Status:
COMPLETED
Long-term Use of Romidepsin in Patients With CTCL
Lead Sponsor:
Northwestern University
Conditions:
Cutaneous T-cell Lymphoma
Eligibility:
All Genders
18-89 years
Brief Summary
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of neoplasm of skin-homing T cells that includes Mycosis Fungoid (MF), which is the most common, Sézary syndrome (SS), the leukemia variant ...
Detailed Description
This project is a retrospective and prospective chart review of patients who present at Northwestern Medical Faculty Foundation clinic with the diagnosis of CTCL. It includes Mycosis Fungoid, Sézary S...
Eligibility Criteria
Inclusion
- Patients with the diagnosis of Cutaneous T-cell Lymphoma who present to the Northwestern Medical Faculty Foundation Dermatology clinic between January 1, 2009 and December 31, 2014
- Stages with more than 20% of bosy surface area affected or higher for MF and SS, and other CTCL variants
- Patients treated with romidepsin
- Between 18 and 89 years
Exclusion
- Patients under 18 and over 89 years
- Patients with the diagnosis of CTCL that did not received romidepsin as a treatment
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT02296398
Start Date
January 1 2015
End Date
August 1 2015
Last Update
March 11 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University Dermatology Department
Chicago, Illinois, United States, 60611